Abstract: The topic of distinguishing atypical fibroxanthoma (AFX) from undifferentiated pleomorphic sarcoma (UPS), formerly malignant fibrous histiocytoma, is highly controversial. Although their clinical behavior is disparate, AFX and UPS commonly appear nearly identical on routine histopathologic examination. Although conceptually useful, subcategorization of UPS into superficial (confined to the dermis and subcutaneous tissue) and deep (involvement of fascia and deeper structures) types has not improved our ability to differentiate UPS from AFX. Numerous authors have purported LN-2 (CD74) immunopositivity as able to distinguish UPS from AFX and to predict those rare AFX likely to behave aggressively, although only a single prior study has been dedicated to evaluating this marker. We performed LN-2 staining of 14 AFX, 8 superficial UPS, and 65 deep UPS specimens using an identical protocol as described by prior authors. Of the 73 total UPS specimens, only 1 (1.4%) stained strongly with LN-2, as compared with 3 of 14 (21%) AFX (P = 0.012). One of 2 (50%) clinically aggressive AFX tumors that later exhibited both local recurrence and metastasis stained strongly for LN-2, whereas 2 of 12 (17%) of the more indolent tumors stained strongly with this marker (P = 0.40). Our data do not replicate prior reports of LN-2 as a sensitive and specific marker for UPS, or as indicative of prognosis for AFX, and therefore does not support the use of LN-2 as either a diagnostic or prognostic marker.
INTRODUCTION
The topic of distinguishing atypical fibroxanthoma (AFX) from undifferentiated pleomorphic sarcoma (UPS), formerly malignant fibrous histiocytoma, is highly controversial. Clearly, the clinical behavior of these tumors is quite different, with AFX representing a neoplasm of low to intermediate malignant potential and UPS more commonly metastasizing and potentially fatal. It is therefore easy to understand why the concept of identifying a specific marker that differentiates these tumors is appealing. LN-2 (CD74), an antigen expressed by B cells, macrophages, and ReedSternberg cells, has been purported to distinguish between UPS and AFX and to discern those uncommon AFX tumors that are prone to local recurrence and metastasis. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] An initial report examined LN-2 expression in a variety of spindle cell lesions of the skin and described 90% of UPS as staining strongly with LN-2, as compared with AFX, where 90% of tumors did not stain with this marker. 1 Several subsequent case series have described UPS and "aggressive" AFX as staining with LN-2, and numerous other authors have further encouraged the use of this marker. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Still, LN-2 is not currently in widespread use, likely because its utility has not been formally confirmed by follow-up studies.
Particularly as the conception of AFX and UPS continues to evolve, identification of a specific immunocytochemical profile would help further characterize these tumors. Some authors have suggested that UPSs are divisible into "superficial," that is confined to the dermis and subcutis, and "deep" subtypes. In fact, superficial UPS is increasingly referred to as "pleomorphic dermal sarcoma" (PDS), to provide clear delineation from the deeper soft tissue-based UPS, although it is not known whether these subtypes represent truly distinct entities and prior studies employing LN-2 have not stratified based on depth of involvement. 1, 8, 14 Confirmation of LN-2 as a diagnostic and prognostic tool would also be valuable from a clinical standpoint, providing guidance regarding the most appropriate workup, management, and surveillance strategies for individual tumors. As such, we analyzed the LN-2 immunoreactivity of a large population of UPS, PDS, and AFX diagnosed at our institution to further evaluate the potential utility of this marker.
MATERIALS AND METHODS
Immunohistochemical (IHC) staining with anti-LN-2 monoclonal antibodies was performed on 73 UPS (including 8 superficial UPS/PDS) and 14 AFX specimens retrieved from the archival tissue banks of our institution. An identical LN-2 clone (CD74; Leica Biosystems, Newcastle upon Tyne, United Kingdom), staining protocol, and grading criteria were employed as those described in the original study of this marker. 1 Inclusion of specimens for analysis required a diagnosis of UPS or AFX from between the years 1995 and 2010 as rendered after formal evaluation by institutional pathologists and dermatopathologists, and uniformly employed immunostaining to rule out other potentially similar-appearing neoplasms. Clinical follow-up data were obtained retrospectively from our institutional database for those patients diagnosed with AFX and PDS in order to evaluate for an association between LN-2 positivity and clinical behavior. Clinical follow-up data were not available for 65 UPS specimens, which had been uniformly harvested from deep soft tissue tumors and included on a tissue microarray. Staining with monoclonal antibodies to LN-2 was performed on the tissue microarray and sectioned tissue blocks of 8 PDS and 14 AFX, where prior adjacent sections had been stained with H&E. 15, 16 The diagnoses within the tissue microarray were confirmed by a pathologist (R.W.) and the diagnoses of the PDS and AFX cases were confirmed by 2 dermatopathologists (K.R. and U.S.), with PDS tumors uniformly centered in the subcutaneous fat and sometimes involving the deep dermis and AFX tumors largely localized to the dermis and occasionally extending to reach the superficial subcutaneous tissues. Normal tonsillar tissue served as a positive control for LN-2.
Grading of immunoreactivity was performed by the authors on a scale of 0 to 3+ as follows: 0 (,10% of the tumor cells staining), 1+ (10%-30%), 2+ (30%-60%), and 3+ (.60%). As per the criteria defined by past investigations of this marker, specimens were deemed as staining strongly positive if .30% of tumor cells were immunoreactive with LN-2. 1 In cases where there was nonconcordance of grading among observers, the case was reviewed and a grade assigned based on discussion between the individual observers. Concordance in grading was .90%. Statistical analysis was performed in order to evaluate for differences in LN-2 immunoreactivity between tumor types using x 2 analysis for a difference of proportions with 2-sided Fischer exact test.
RESULTS
The immunoreactivity of the tissue specimens for LN-2 is summarized in Table 1 and demonstrated in Figures 1A-C (PDS/superficial UPS) and Figures 1D-I (AFX) . Of the total 73 UPS specimens, 1 (1.4%) was strongly positive (Fig. 1A-C) , as compared with 3 of the 14 (21%) AFX (P = 0.012). Eight of the UPS specimens (11%) stained weakly positive for LN-2. The control specimens uniformly stained strongly with LN-2, as did lymphocytes surrounding inflamed tumor specimens.
Clinical characteristics of the AFX and PDS/superficial UPS tumors, along with LN-2 immunoreactivity, are summarized in Table 2 . Patients with AFX ranged in age from 50 to 90 years (mean 76.4 years). All tumors arose on the head and neck region, with the majority involving the face and ear (71.4%). Each tumor was confined to the dermis, although 4 biopsy specimens were insufficient to enable evaluation of the deep margin. One of the 2 (50%) AFX that exhibited both local recurrence and metastasis stained strongly for LN-2 (Figs. 1D-F) , whereas 2 of 12 (17%) of the more indolent tumors stained strongly with this marker (P = 0.40). Both of the clinically aggressive AFX had been transected on initial shave biopsy, precluding evaluation of the deep margin at the time of diagnosis.
Patients diagnosed with PDS ranged in age from 62 to 90 years (mean 77.6 years). All tumors arose on the head and neck region, with a predominance of scalp lesions (75%). Histopathologic analysis of each tumor revealed infiltration of the subcutis. One of 8 (12.5%) PDS specimens stained strongly with LN-2 (Figs. 1A-C) . On clinical follow-up, 5 PDS tumors exhibited local recurrence, 1 (20%) of which stained strongly with LN-2. Two superficial UPS ultimately metastasized, and neither tumor stained with LN-2.
DISCUSSION
The purpose of this study was to establish whether LN-2 immunoreactivity differentiates UPS from AFX and predicts which rare AFX tumors are likely to recur or metastasize, as first described by Lazova and colleagues [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] and later purported by numerous authors. Our results do not support the utility of LN-2 as either a diagnostic or prognostic marker, despite our use of an identical antibody clone, staining protocol, and numeric scoring system to evaluate the largest group of specimens to date. Only 1.4% of UPS stained strongly with LN-2, as compared with 21% of AFX (Table 1 ). Although our sample sizes of AFX and PDS are somewhat limited, immunoreactivity with LN-2 did not seem to correlate with clinical behavior in this population (Table 2) .
Overall, the clinical characteristics of tumors in our study were highly consistent with prior reports. AFX and superficial UPS/PDS most commonly develop in elderly males, typically arising on the head and neck. 4, 17, 18 The average patient age in our population was 77.3 years (range 50-90 years), and all tumors involved the head and neck region. Rates of recurrence and metastasis were also similar to those of previous reports. 4, 17, 18 Of the 8 patients with PDS, 5 (63%) experienced local recurrence after surgery and 2 (25%) ultimately developed widespread metastases. In contrast, the patients with AFX fared relatively well, with only 2 of 14 (14%) experiencing recurrent and metastatic disease. As both of these "aggressive" AFX were transected deeply on initial diagnostic biopsy specimens, and excisional specimens were not available, we cannot say for certain that these tumors did not actually represent PDS, thus reinforcing the necessity of obtaining an adequate sample before rendering a final diagnosis.
Although no studies have demonstrated progression from AFX to superficial UPS, the similar patient, tumor, and IHC characteristics would seem to indicate a close relationship between these tumors. 8 In our study, depth of tumor infiltration proved to be the most reliable diagnostic and prognostic feature, rather than LN-2 staining. Unfortunately, we were not able to access clinical follow-up data for the population of deep UPS contained on the tissue microarrays, although all these tumors arose from soft tissue structures, with diagnosis confirmed by a comprehensive workup including IHC, and with tumor visualized directly on each specimen stained with LN-2. The discordance between our results and that of Lazova et al is an interesting finding. It is possible that morphologic scoring differences may exist. We were careful to only score large pleomorphic atypical cells within the infiltrate, but it is not clear from our own personal experience, and from studies in the literature, if the background smaller cells in these tumors also constitute part of the atypical proliferation. Complicating the analysis is the fact that LN-2 is positive within lymphocytes and all 3 entities within this study tend to be rich in lymphocytes. In addition, as the article of Lazova et al was published 15 years ago, changes in staining solutions and reagents may also be playing a role. Finally, although our cases of superficial UPS and AFX were studied on conventional sections, our cases of deep UPS were examined on a tissue microarray. Although studies have shown that conventional tissue sections and tissue arrays yield very similar results, 15, 16 and large atypical cells were present in all assessed deep UPS specimens, it is possible that sampling may be the cause of the discrepancy between our results and those published in the literature.
As has been discussed extensively elsewhere, the topic of distinguishing AFX from UPS is highly controversial, with some authors pointing to potential differences in genetic makeup as evidence of 2 distinct entities, and others indicating that AFX and UPS merely comprise 2 ends of the same spectrum. 4, [17] [18] [19] [20] [21] This is compounded by the nearly identical appearance of these tumors on routine light microscopy, where the dermis, subcutis, and deep soft tissues serve as rough lines of demarcation differentiating among AFX, PDS, and conventional UPS, respectively. Furthermore, numerous prior investigators have compared AFX and UPS by IHC studies without finding a reliable marker for differentiating these two entities. 22, 23 As such, it is easy to understand why the potential utility of LN-2 continues to be referenced despite only 1 prior study fully dedicated to its evaluation. 1, [8] [9] [10] [11] [12] [13] Unfortunately, our data did not corroborate prior reports of LN-2 as a useful diagnostic and prognostic marker. Future developments in IHC and molecular technologies will likely afford further insight into these neoplasms and provide increasingly useful clinical guidance.
